These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11367508)

  • 61. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
    Albert MA; Danielson E; Rifai N; Ridker PM;
    JAMA; 2001 Jul; 286(1):64-70. PubMed ID: 11434828
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anti-inflammatory effects of hydrophilic and lipophilic statins with hyaluronic acid against LPS-induced inflammation in porcine articular chondrocytes.
    Chang CH; Hsu YM; Chen YC; Lin FH; Sadhasivam S; Loo ST; Savitha S
    J Orthop Res; 2014 Apr; 32(4):557-65. PubMed ID: 24302463
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1α expression and redox status in B16.F10 melanoma cells.
    Alupei MC; Licarete E; Cristian FB; Banciu M
    Anticancer Drugs; 2014 Apr; 25(4):393-405. PubMed ID: 24441744
    [TBL] [Abstract][Full Text] [Related]  

  • 64. LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
    de Bont N; Netea MG; Rovers C; Smilde T; Demacker PN; van der Meer JW; Stalenhoef AF
    Atherosclerosis; 1998 Jul; 139(1):147-52. PubMed ID: 9699902
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes.
    Massonnet B; Normand S; Moschitz R; Delwail A; Favot L; Garcia M; Bourmeyster N; Cuisset L; Grateau G; Morel F; Silvain C; Lecron JC
    Eur Cytokine Netw; 2009 Sep; 20(3):112-20. PubMed ID: 19825520
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Statins: the new aspirin?
    Veillard NR; Mach F
    Cell Mol Life Sci; 2002 Nov; 59(11):1771-86. PubMed ID: 12530513
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates.
    Kitamoto S; Nakano K; Hirouchi Y; Kohjimoto Y; Kitajima S; Usui M; Inoue S; Egashira K
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1522-8. PubMed ID: 15178560
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions.
    Weber C; Erl W; Weber KS; Weber PC
    Clin Chem Lab Med; 1999 Mar; 37(3):243-51. PubMed ID: 10353467
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Influence of high cholesterol diet and pravastatin sodium on the initiation of liver regeneration in rats after partial hepatectomy.
    Zivna H; Zivny P; Palicka V; Simakova E
    Nutrition; 2002 Jan; 18(1):51-5. PubMed ID: 11827765
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
    Demyanets S; Kaun C; Pfaffenberger S; Hohensinner PJ; Rega G; Pammer J; Maurer G; Huber K; Wojta J
    Biochem Pharmacol; 2006 Apr; 71(9):1324-30. PubMed ID: 16540096
    [TBL] [Abstract][Full Text] [Related]  

  • 71. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
    Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
    Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
    [TBL] [Abstract][Full Text] [Related]  

  • 72. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
    Wang E; Casciano CN; Clement RP; Johnson WW
    Pharm Res; 2001 Jun; 18(6):800-6. PubMed ID: 11474784
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Selective inhibition of formyl-methionyl-leucyl-phenylalanine (fMLF)-dependent superoxide generation in neutrophils by pravastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.
    Kanno T; Abe K; Yabuki M; Akiyama J; Yasuda T; Horton AA
    Biochem Pharmacol; 1999 Dec; 58(12):1975-80. PubMed ID: 10591153
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
    Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104).
    Han J; Parsons M; Zhou X; Nicholson AC; Gotto AM; Hajjar DP
    Circulation; 2004 Nov; 110(22):3472-9. PubMed ID: 15557368
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
    Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
    Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes.
    Delbosc S; Morena M; Djouad F; Ledoucen C; Descomps B; Cristol JP
    J Cardiovasc Pharmacol; 2002 Oct; 40(4):611-7. PubMed ID: 12352324
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
    Joukhadar C; Klein N; Prinz M; Schrolnberger C; Vukovich T; Wolzt M; Schmetterer L; Dorner GT
    Thromb Haemost; 2001 Jan; 85(1):47-51. PubMed ID: 11204586
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells.
    Inoue I; Goto S; Mizotani K; Awata T; Mastunaga T; Kawai S; Nakajima T; Hokari S; Komoda T; Katayama S
    Life Sci; 2000 Jul; 67(8):863-76. PubMed ID: 10946846
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Istvan ES
    Am Heart J; 2002 Dec; 144(6 Suppl):S27-32. PubMed ID: 12486413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.